Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ruizhen, Luo"'
Purpose: The clinical outcomes of de novo metastatic breast cancer (dnMBC) differ between estrogen receptor (ER)-positive and ER-negative patients, but the respective prognostic factors in these two subpopulations have not been established. This stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2934cec66a2b136848855d91af59277d
https://doi.org/10.21203/rs.3.rs-2765078/v1
https://doi.org/10.21203/rs.3.rs-2765078/v1
Autor:
Haoqi Wang, Yueping Liu, Hua Yang, Shuaibing Wang, Guozhong Cui, Jie Ma, Yunjiang Liu, Xianqiao Li, Ruizhen Luo, Wei Zhang, Cuizhi Geng
Publikováno v:
Journal of Clinical Oncology. 40:1040-1040
1040 Background: Pyrotinib, an irreversible pan-ErbB inhibitor, has been approved for the treatment of HER2-positive advanced breast cancer in China. Real-world data is instructive for effect evaluation and application of the drug in clinical practic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7363e3ee0528e53bbe7040d94a2a8760
https://doi.org/10.1200/jco.2022.40.16_suppl.1040
https://doi.org/10.1200/jco.2022.40.16_suppl.1040
Publikováno v:
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pe13049-e13049, 1p